MVASI

Amgen Inc🇺🇸 United States

FDA Page

Effective Date: Jun 23, 2026
Approval ID: 0a562b4e-67ce-4bab-852c-d9ee71e55fb8
Products: 2 registered
Version: 23

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI. MVASI (bevacizumab-awwb) injection, for intravenous use Initial U.S. Approval: 2017 MVASI (bevacizumab-awwb) is biosimilar to AVASTIN (bevacizumab)

Quick Stats

Total Products2

Labelers3

Label Sections35

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.